| 2025 | 2024 | 2023 | 2022 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 2,4 M € | +25.9% | 1,9 M € | +6.5% | 1,8 M € | +21.7% | 1,5 M € | +72.2% | 854,0 k € | +49.3% | 572,0 k € | -5.7% | 606,4 k € | +15.5% | 525,0 k € | +18.1% | 444,7 k € | +66.2% | 267,6 k € | -2.7% | 275,1 k € | +22.4% | 224,8 k € | -17.4% | 272,0 k € | +36.6% | 199,1 k € | +34.1% | 148,4 k € | |
| EBITDA | 1,2 M € | +24.1% | 988,2 k € | -11.4% | 1,1 M € | +20.1% | 928,7 k € | +219.1% | 291,1 k € | +180.1% | 103,9 k € | -20.9% | 131,3 k € | +7.2% | 122,5 k € | +183.9% | 43,2 k € | -6.5% | 46,2 k € | -50.4% | 93,1 k € | +142.7% | 38,3 k € | -67.1% | 116,3 k € | +72.8% | 67,3 k € | -23.0% | 87,5 k € | |
| Operating profit | 1,2 M € | +24.0% | 987,6 k € | -11.5% | 1,1 M € | +20.1% | 928,7 k € | +220.0% | 290,2 k € | +185.1% | 101,8 k € | -20.1% | 127,4 k € | +11.1% | 114,7 k € | +233.4% | 34,4 k € | +8.6% | 31,7 k € | -59.4% | 78,0 k € | +187.4% | 27,1 k € | -74.3% | 105,8 k € | +74.5% | 60,6 k € | -28.6% | 84,9 k € | |
| Profit/loss | 910,0 k € | -7.6% | 984,9 k € | -13.6% | 1,1 M € | +21.4% | 939,1 k € | +233.6% | 281,5 k € | +201.8% | 93,3 k € | -24.6% | 123,8 k € | +15.0% | 107,6 k € | +266.9% | 29,3 k € | +7.8% | 27,2 k € | -65.2% | 78,2 k € | +204.4% | 25,7 k € | -75.4% | 104,6 k € | +160.3% | 40,2 k € | -21.3% | 51,1 k € | |
| Equity | 69,3 k € | 0.0% | 69,3 k € | 0.0% | 69,3 k € | 0.0% | 69,3 k € | 0.0% | 69,3 k € | 0.0% | 69,3 k € | 0.0% | 69,3 k € | 0.0% | 69,3 k € | 0.0% | 69,3 k € | 0.0% | 69,3 k € | 0.0% | 69,3 k € | 0.0% | 69,3 k € | 0.0% | 69,3 k € | -9.2% | 76,3 k € | +15.4% | 66,1 k € | |
| Total assets | 1,5 M € | +10.8% | 1,3 M € | -10.2% | 1,5 M € | +24.3% | 1,2 M € | +95.8% | 610,2 k € | +36.6% | 446,8 k € | +55.2% | 287,9 k € | -22.2% | 370,0 k € | -1.1% | 374,0 k € | +127.4% | 164,5 k € | -14.8% | 193,1 k € | +63.8% | 117,9 k € | -57.6% | 278,4 k € | +103.1% | 137,1 k € | -26.3% | 186,0 k € | |
| Cash | 334,0 k € | +155.5% | 130,7 k € | +28.9% | 101,4 k € | -79.1% | 484,5 k € | +92.8% | 251,2 k € | +20.8% | 208,0 k € | +332.0% | 48,1 k € | -69.7% | 159,0 k € | +1334.6% | 11,1 k € | -28.2% | 15,4 k € | -48.3% | 29,9 k € | +61.5% | 18,5 k € | -84.9% | 122,6 k € | +64.1% | 74,7 k € | -9.9% | 83,0 k € | |
| Debts | 1,4 M € | +11.0% | 1,3 M € | -10.8% | 1,4 M € | +25.8% | 1,1 M € | +108.1% | 540,9 k € | +43.3% | 377,5 k € | +72.7% | 218,6 k € | -27.3% | 300,7 k € | -1.3% | 304,7 k € | +220.1% | 95,2 k € | -23.1% | 123,8 k € | +154.7% | 48,6 k € | -76.7% | 209,1 k € | +243.9% | 60,8 k € | -48.3% | 117,7 k € | |
| Staff | 15,1 | 11,3 | 8,6 | 8,9 | 6,8 | 6 | 6,4 | 5,5 | 4,6 | 4,6 | 3,1 | 3,7 | 3,5 | 2,6 | 1,6 | |||||||||||||||
Public limited company · Kampenhout · incorporated on 29/01/2008 · 15,1 ETP
Public limited company profitable but thinly capitalised. Cash position rising (+155.5%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure — thin equity (69,3 k €) relative to earnings. The abridged model hides revenue.
| Unit no. | Name | Location |
|---|---|---|
| 2231419078 | IN2PHARMA | Terloonststraat 22, 1910 Kampenhout |
| 2388528493 | IN2PHARMA | Kerkstraat 108, 9050 Gent |
IN2PHARMA is a Public limited company incorporated in 2008. Its main activity is: Activités de conseil pour les affaires et autre conseil de gestion. Its registered office is in Kampenhout. It employs on average 15,1 ETP workers (FTE).
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette